- Open Access
Highly activated p53 contributes to selectively increased apoptosis of latently HIV-1 infected cells upon treatment of anticancer drugs
Virology Journal volume 13, Article number: 141 (2016)
Despite the successful inhibition of human immunodeficiency virus type 1 (HIV-1) replication by combination antiretroviral therapy, cells latently infected with HIV-1 remaining in patients are a major obstacle for eradication of HIV-1 infection. The tumor suppressor factor p53 is activated by HIV-1 infection, and restricts HIV-1 replication. However, a therapeutic strategy based on p53 activity has not been considered for elimination of latently infected cells.
Apoptotic cells were analyzed using flow cytometry with anti-annexin A5-FITC Ab and PI staining upon treatment of anticancer drugs. The expression and activation of p53 and apoptotic molecules in latently HIV-1-infected T cells were compared using Western blot analysis. The role of p53 in the anticancer drug treatment-induced apoptosis of cells latently infected with HIV-1 was determined by knock-down experiment using siRNA against p53.
Upon treatment with 5-fluorouracil (5-FU), apoptosis was increased in latently infected ACH2 cells encoding competent p53 compared with uninfected parent A3.01 cells, while the apoptosis of latently infected p53 null J1.1 cells was less than that of uninfected cells. Treatment with 5-FU increased the levels of cleaved caspase-3 and PARP in ACH2 cells compared with uninfected and latently infected p53 null J1.1 cells. The levels of expression and activation of p53 were higher in both latently infected ACH2 and NCHA2 cells than in uninfected cells. Furthermore, the activation levels of p53 in both cells were further increased upon 5-FU treatment. Consistent with p53 status, apoptosis was markedly increased in ACH2 and NCHA2 cells compared with uninfected and latently infected J1.1 cells upon treatment with other anticancer drugs such as doxorubicin and etoposide. Inhibition of p53 in cells with latent HIV-1 infection diminished apoptosis upon 5-FU treatment.
Evidence described here indicate that when treated with anticancer drugs, apoptosis of cells with latent HIV-1 infection was increased via the p53 activation pathway and may provide information for application of anticancer drugs to selectively eliminate HIV-1 reservoirs.
Persistent human immunodeficiency virus type 1 (HIV-1) infection causes a progressive loss of CD4+ T cells, followed by acquired immunodeficiency syndrome (AIDS) [1, 2]. Although highly active antiretroviral therapy (HAART) can improve the life-span of HIV-1 infected patients by successful suppression of the HIV-1 replication, HAART is not able to eliminate the latent reservoir established early during infection . Accordingly, latent reservoirs of HIV-1 infection have importantly been recognized as a major barrier to HIV-1 eradication [4, 5].
Numerous strategies for the elimination of latent HIV-1 infection have been investigated. These strategies include intensive ART regimens, transplantation of CCR5-deleted bone marrow, and reactivation of HIV-1 expression. One of the most innovative strategies aims to awaken the latent virus and thereby increase the killing of the latent infection reservoir by the immune system, known as “shock and kill”, and uses T-cell activating cytokines (IL-7), T-cell receptor signaling pathway activators (bryostatin and prostratin as a protein kinase C activator), histone deacetylase inhibitors (valproic acid, vorinostat (suberoylanilide hydroxamic acid)), DNA methylase inhibitors, and disulfiram . Although these reactivating strategies have recently been shown to increase viral RNA in patients, reduction of reservoir size has not been consistently successful.
Tumor suppressor p53 plays a key role in the stimulation of cell apoptosis and growth arrest through a cooperative signaling network of genotoxic stress caused by treatment with anticancer drugs, irradiation, ultraviolet light, and glucose starvation . HIV-1 infection also induces genotoxic stresses linked to p53 activation in CD4+ T cells by integration mediated- dsDNA strands break, secretion of type I interferons and expression of HIV-1 accessory proteins Vpr/Vpu, which may be considered as intracellular markers of HIV-1 infection [8–11]. The p53 activation by HIV-1 infection also plays an important role in host-restriction mechanisms against HIV-1 replication, which suppress long terminal repeat (LTR)-mediated viral transcription through Tat modulation .
With regard to apoptosis of HIV-l infected cells, an earlier report showed that latently HIV-l infected H9, J1.1 and U1 cells that are p53 null were more resistant to apoptosis than their uninfected parent cells under treatment with H2O2 and staurosporine (STS) which leads to an increase in oxidative stress rather than genotoxic stress . In a recent study, ACH2 and U1 cells showed induction of HIV-1 reactivation by an alternative replication program (ARP) during cell apoptosis after cytotoxic drug treatment . Although these studies suggested that apoptosis might be an important characteristic of latent HIV-1 infection, these data might be missed by an examination of p53 status and comparative analysis of the apoptotic ratio between the latently infected and uninfected cells. Currently, the important roles of p53 have been discussed in HIV-1 infection. However, the p53-mediated apoptosis of latently infected cells by treatment of anticancer drugs has not been considered in developing strategies for eliminating cells latently infected with HIV-1. Herein, we hypothesize that apoptosis may be more sensitively induced in latently infected cells encoding competent p53 than uninfected cells upon treatment with anticancer drugs. We found that anticancer drugs greatly enhanced apoptosis of latently infected cells compared with uninfected cells, and knockdown of p53 significantly diminished the apoptosis. Our data suggest that anticancer drugs may be useful agents for selectively purging HIV-1 reservoirs.
Cells, anticancer drugs and antibodies
A3.01 and cell lines latently infected with HIV-1 (A3.01-derived ACH2 and Jurkat-derived J1.1) were obtained from the NIH AIDS Research and Reference Reagent Program. Latently infected A3.01-derived NCHA2 cells were established in our laboratory . Cells were cultured as previously described . Briefly, cells were maintained in RPMI medium (Gibco-BRL) supplemented with 1 % L-glutamine, 1 % penicillin–streptomycin, and 10 % (v/v) heat-inactivated fetal bovine serum (FBS; Gibco-BRL) in an incubator at 37 °C under an atmosphere of 5 % CO2. The anticancer drugs, 5-fluorouracil (5-FU), doxorubicin, and etoposide were purchased from Sigma-Aldrich (USA) and treated with the concentrations indicated in previous reports [16–19]. Antibodies (Ab) against caspase-3, cleaved caspase-3, PARP, Bax, puma, phosphor-S15-p53, and β-actin were obtained from Cell Signaling Technology (USA). Anti-p53 antibodies (DO-1) were obtained from Santa Cruz Biotechnology (USA).
Flow cytometric analysis of apoptosis
Early apoptotic (annexin A5-FITC-positive, propidium (PI)-negative) and late apoptotic (annexin A5-FITC-positive, PI-positive) cells were analyzed using flow cytometry with anti-annexin A5-FITC Ab and PI staining . Briefly, cells treated with 5-FU for 24 h were then incubated with anti-annexin A5-FITC Ab and PI (Calbiochem) for 10 min at room temperature. The stained cells were detected using a FC500 flow cytometer and analyzed with RXP1.0 software (Beckman Coulter). The analysis of sub-G1 cell populations has been described previously [19, 21]. Briefly, cells were incubated with drugs for 36 h. Cells were then fixed with 70 % ice-cold ethanol and incubated overnight at 4 °C. Fixed cells were incubated with 100 μg RNase A at 37 °C for 1 h and stained with 50 μg/ml of PI. For measurement of intracellular DNA content, at least 10,000 events were analyzed. All experiments were performed independently at least three times.
Western blot analysis
Western blot analysis was performed as previously described . Briefly, cells were treated with an anticancer drug, 5-FU, doxorubicin, or etoposide for 12 h and then harvested in RIPA buffer (Cell Signaling Technology) containing a complete EDTA-free protease and phosphatase inhibitor cocktail (Roche). Forty μg of protein extract was subjected to 10 % sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) and transferred onto polyvinylidene difluoride membranes (Millipore). The membranes were incubated with appropriate antibodies and then visualized by chemiluminescence using Image Lab software (Bio-Rad) according to the manufacturer’s protocols.
Knockdown and ectopic expression of p53
Five synthesized p53 siRNAs were purchased from Invitrogen. Their sequences were as follows: No. 1 (VHS40366): CCA UCC ACU ACA ACU ACA UGU GUA A, No. 2 (VHS40367): CCA GUG GUA AUC UAC UGG GAC GGA A, No. 3 (HSS110905): GCU UCG AGA UGU UCC GAG AGC UGA A, No. 4 (HSS186390): GAG UGG AAG GAA AUU UGC GUG UGG A, and No. 5 (HSS186391): CCG CCU GAG GUU GGC UCU GAC UGU A. Knockdown of p53 was performed by electroporation as described previously . Briefly, 1 × 107 cells were electroporated with 500 pmole of control siRNA (si-con; Invitrogen) or p53 siRNAs in 0.4 cm cuvettes at 960 μF and 250 V. The ectopic expression of p53 in J1.1 cells was performed by electroporation using a Nucleofector™ kit X (Lonza) with 5 μg of pcDNA3- Flag-tagged p53 according to the manufacturer’s protocol .
The data are expressed as their mean value ± standard deviation (SD). The data were compared using Student t tests and p <0.05 was considered a significant difference.
Distinct sensitivity of cells latently infected with HIV-1 to apoptosis upon 5-FU treatment
Although numerous previous investigations have shown apoptosis of cells infected with HIV-1, apoptosis of latently infected cells is as yet little known. To address this issue, we compared the apoptotic ratio between latently infected cells and uninfected cells in the presence of anticancer drug-induced genotoxic stress. As shown in Fig. 1a, using flow cytometry analysis, two cell lines latently infected with HIV-1 (ACH2 and J1.1) and an uninfected cell line (A3.01) all showed increased apoptosis after treatment with 5-FU. Notably, we found greatly increased apoptosis in latently infected ACH2 cells compared with other cells examined. However, the other latently infected cells, J1.1, showed slightly decreased level of apoptosis in comparison with uninfected A3.01 cells upon 5-FU treatment. These phenomena were observed in both early and late apoptosis (Fig. 1a). The proteolysis of caspase-3 and its substrate PARP occurring in cells undergoing apoptosis was dramatically increased in latently infected ACH2 cells by 5-FU treatment, whereas proteolysis was barely detected in uninfected A3.01 and latently infected J1.1 cells (Fig. 1b). These data indicate that after 5-FU treatment, cells latently infected with HIV-1 have a distinctive cell fate based on their distinct cellular machinery.
Tumor suppressor p53 is linked to the 5-FU treatment-induced apoptosis of cells latently infected with HIV-1
Next, we sought to determine which cellular modulator is associated with the distinctive fate of latently infected cells during 5-FU-induced apoptosis. Previous studies showed that p53 was activated in cells acutely infected with HIV-1. Consistent with acute infection, the expression of p53 was increased in latently infected ACH2 cells compared with their parent A3.01 cells. Notably, the phosphorylation level of p53 was significantly enhanced in ACH2 cells despite the lack of a specific stimulus, which might be caused by latent infection-induced stresses (Fig. 2a, upper panel). However, the expression of p53 was not detected in latently infected J1.1 cells originating from the Jurkat cell line that is known as p53 defective. Moreover, the increased levels of total and phosphorylated p53 in ACH2 cells were further enhanced by 5-FU treatment compared with those in A3.01 cells, while J1.1 cells showed no expression of p53 despite this stimulus (Fig. 2a, lower panel). To evaluate p53-mediated cell apoptosis in latently infected cells upon genotoxic stress, the molecules downstream of p53 in latently infected ACH2 and NCHA2 cells that express the wild-type p53 were examined in the presence and absence of 5-FU. The levels of expression of Bax, puma, and p21 which are well known as p53 target genes, were highly elevated together with the levels of p53 activation in ACH2 and NCHA2 cells when cells were treated with 5-FU, while the increased levels were modest in uninfected cells (Fig. 2b). To confirm the p53-linked cell apoptosis in latently infected cells, p53 null J1.1 cells were ectopically expressed with p53 upon 5-FU treatment. The cells ectopically expressed with p53 showed increased apoptosis upon 5-FU treatment compared with mock expression. Furthermore, the treatment of the p53 inhibitor, pifithrin-α, in the cells showed diminished apoptosis compared with vehicle-treated J1.1 cells expressed with p53 (Fig. 2c). Unpredictably, the levels of apoptosis induced by ectopic p53 expression were lower than those of the p53 competent cells latently infected with HIV-1. These data indicate that the cell fate linked to apoptosis in cells latently infected with HIV-1 was likely to be dependent on the status of p53 upon treatment with anticancer drugs such as 5-FU.
Induced genotoxic stress and increased apoptosis of cells latently infected with HIV-1 upon anticancer drug treatment
Anticancer drugs effectively promote cell apoptosis linked to genotoxic stress inducing p53 activation. Given this background, we sought to determine whether other types of anticancer drugs can selectively induce p53-mediated apoptosis of cells latently infected with HIV-1. Anticancer drugs including etoposide and doxorubicin, widely used in cancer therapy, were used to treat p53 competent ACH2 and NCHA2 cells as well as p53 null J1.1 cells. In an analysis of sub-G1 DNA content, the sub-G1 population of ACH2 and NCHA2 cells was markedly increased in comparison with uninfected A3.01 cells after etoposide or doxorubicin treatment similarly with 5-FU treatment. Unlike p53 competent cells, p53 null J1.1 cells showed slight resistance to apoptosis (Fig. 3a). The p53 phosphorylation levels were greatly increased in latently infected ACH2 and NCH2 cells in the presence of anticancer drugs in comparison with uninfected cells, whereas J1.1 cells did not show p53 expression after any drug treatment (Fig. 3b). These findings suggest that apoptosis of cells latently infected with HIV-1 might be induced by widely used anticancer drugs via p53 activation.
p53 plays a pivotal role in the anticancer drug-induced increased apoptosis of cells latently infected with HIV-1
To determine whether p53 plays a key role in the anticancer drug treatment-induced apoptosis of cells latently infected with HIV-1, siRNA against p53 was introduced into latently infected ACH2 and NCHA2 cells. The levels of expression of p53 were efficiently diminished in cells electroporated with No.1 p53 siRNA (Fig. 4a upper), and the p53 knockdown with the chosen siRNA was efficient in ACH2 and NCHA2 cells even upon 5-FU treatment (Fig. 4a lower). The knockdown of p53 by the siRNA significantly reduced the sub-G1 populations of latently infected ACH2 and NCHA2 cells in the presence of 5-FU (Fig. 4b), which may conceivably be the result of disruption of the p53 downstream pathway, triggering cell apoptosis. The role of p53 in the apoptosis of these cells upon 5-FU treatment was further evidenced with the p53 inhibitor. As shown in Fig. 4c, pifithrin-α treatment diminished cell apoptosis in both the ACH2 and NCHA2 cells upon 5-FU treatment. These data suggested that after anticancer drug treatment, the latently infected cells were sensitive to apoptosis via a p53 linked-pathway.
During the clinical course of HIV-1 infection, latently HIV-1 infected provirus is present in the long-lived CD4+ T memory cells that play a role as a steady source of infectious viral particles after interruption of treatment and as a major obstacle to HIV-1 eradication [4, 5]. Eliminating such HIV-1 reservoirs is a great challenge, because a selective marker by which to target the reservoir latently infected with HIV-1 has not yet been discovered.
HIV-1 infection can facilitate p53 expression and activation in T cells by integration-mediated host chromosomal abnormality and/or Vpr-induced DNA damaged-stress and Vpu-mediated stabilization of p53 [8, 10, 11, 23]. The induced p53 may play roles in the host restriction of HIV-1 replication and in the apoptosis of cells acutely infected with HIV-1. Anticancer drugs such as 5-FU, doxorubicin, and etoposide are well known to induce genotoxic stress linked to p53 activation followed by cell apoptosis. Although important roles for p53 in HIV-1 infection have been considered, utilization of anticancer drugs to activate p53 and selectively eliminate cells latently infected with HIV-1 has not been addressed.
In the present study, 5-FU induced the early and late apoptosis of latently infected ACH2 cells compared with latently infected J1.1 and uninfected A3.01 cells. Moreover, the levels of intracellular apoptotic markers such as cleaved caspase-3 and PARP were markedly increased in ACH2 cells compared with those in other cells (Fig. 1). The uninfected A3.01 cells that is p53 competent also showed significantly increased apoptosis upon 5-FU treatment compared with that of p53 defective J1.1 cells, while the levels were lower than those of the latently infected ACH2 cells derived from A3.01 cells. These data reveal that the differences in status of p53 among uninfected and latently infected cells (Fig. 2a) may lead to p53 dependent tendencies toward apoptosis upon genotoxic stress (Figs. 1, 2 and 3). Larrosa et al. showed that H9, J1.1, and U1 cells latently infected with HIV-1 were resistant to cytotoxic substances such as H2O2 and STP when compared with their uninfected parent cells . However, their findings may do not support the resistance to apoptosis of latently infected cells in general, because the cells they used were all p53 null cell lines, which showed resistance to apoptosis upon substance-induced stress. Consistent with a previous report, our data also showed that p53 null J1.1 cells were more resistant to apoptosis upon genotoxic stress than uninfected A3.01 (Figs. 1 and 3) and Jurkat cells (data not shown). Together, these data indicate that latent HIV-1 infection may prevent apoptosis of the host cell to promote longer survival of the cells by an as yet unknown mechanism in the absence of p53, but HIV-1 infection may facilitate the apoptosis of cells susceptible to HIV infection that have competent p53. Although p53 is known to be a key factor in inducing apoptosis in anticancer drug treated cells, the p53 null J1.1 cells still showed small amounts of cell death. These data indicated that the cells were undergoing apoptosis by the p53-independent pathway such as p73 , Bid , MCL2  and ATM/E2F1  that were showed in its parent Jurkat cells upon the genotoxic stresses.
Western blot analysis of p53 target gene proteins showed that the levels of Bax, puma, and p21, which are the best-known p53 targets, were greatly increased in latently infected cells expressing p53 upon 5-FU treatment. As such, these gene products may contribute to the sensitivity of cells to apoptosis. Although the 5-FU treated A3.01 cells and the J1.1 cells expressed with ectopic p53 also showed increased levels of apoptosis compared with the untreated cells, the levels were much weaker than those of the p53 competent cells infected with HIV-1. The data indicated that the insufficient level of p53 activation and the alternative pathway of p53 could not greatly increase apoptosis, as shown in the ACH2 and NCHA2 cells. CD4+ T lymphocyte depletion linked to HIV-1 infection has been explained by numerous mechanisms including abortive infection-induced pyroptosis , DNA-dependent protein kinase , Fas-ligand , p53 activation  and viral proteins Nef and Vpr [31, 32]. These observations sufficiently explained the apoptosis as a result of acute HIV-1 infection. Genini et al. suggested that activation of p53 by acute HIV-1 infection may contribute to the depletion of HIV-1 infected T cells . The present data also showed that latently infected cells, which are p53 competent, showed an increased level of phosphorylated p53 and its target genes in the absence of drugs, similarly to acute infection. However, the slight enhancement of p53 activation in the latently infected cells might not be sufficient to trigger apoptosis. Accordingly, genotoxic stress induced by anticancer drugs promoted the p53 activation synergistically leading to apoptosis of latently infected cells.
Numerous anticancer drugs have been developed and used for the cure of cancerous disease. Among them, 5-FU, an inhibitor of thymine synthetase, doxorubicin, an inhibitor of topoisomerase II, and etoposide, an inhibitor of topoisomerase I, are widely used in the treatment of cancers . Although the drugs act on different enzymes linked to chromosomal DNA, these drugs commonly induce DNA stress followed by p53 activation-induced apoptosis. Based on the mechanisms of action of these drugs, 5-FU and doxorubicin/etoposide efficiently induced p53 activation in latently infected cells, followed by apoptosis, but not in p53 null J1.1 cells (Figs. 1 and 3). A new generation of anticancer drug, such as taxane, which inhibit the microtubule synthesis during mitosis unlinked to DNA-damaging stress, are used widely . Therefore, p53-mediated apoptosis by the drug should determine whether the drug selectively induces the apoptosis of latently infected cells.
To determine the exact role of p53 in apoptosis of latently infected cells upon treatment with an anticancer drug, p53 siRNAs and a p53 inhibitor were employed. Both could reduce the apoptosis of the cells upon 5-FU treatment. The diminished apoptosis in the ACH2 and NCHA2 cells by p53 siRNA and the inhibitor indicated that p53 played an important role in the anticancer drug-induced apoptosis (Fig. 4). However, the siRNA and the inhibitor could not completely reduce the apoptosis. The results might have been caused by the p53-independent pathways and the incomplete efficacy of the siRNA and the inhibitor. A mechanism underlying viral reactivation in response to anticancer drugs has been proposed . However, the data presented did not show distinctive apoptotic fates between cells because they focused on viral reactivation in the reservoir cells during anticancer drug-induced apoptosis without comparison to uninfected parent cells or assessing p53 status.
Although several methodologies for isolation of latently infected cells ex vivo have been developed, studying the functional role of those cells is so far difficult. There are lot of hurdles, such as the rarity of reservoirs (<1 per 106 CD4+ T cells), the absence of suitable markers by which to isolate cells and T-cell activator treatments for surmounting the rarity, which may activate a variety of cellular signals . Therefore, evaluation of p53-mediated apoptosis of latently infected cells in vivo and ex vivo remains for further study.
We conclude that anticancer drugs may be useful agents for selectively purging HIV-1 reservoirs and might contribute to insights for future therapeutic strategies to promote complete viral eradication.
Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol. 2007;5(2):95–106.
Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011;1(1):a007096.
Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol. 2009;7(11):798–812.
Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today. 2013;18(11–12):541–51.
Siliciano JD, Siliciano RF. Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. J Allergy Clin Immunol. 2014;134(1):12–9.
Rasmussen TA, Tolstrup M, Winckelmann A, Ostergaard L, Sogaard OS. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother. 2013;9(4):790–9.
Janicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 2008;15(6):959–76.
Genini D, Sheeter D, Rought S, Zaunders JJ, Susin SA, Kroemer G, et al. HIV induces lymphocyte apoptosis by a p53-initiated, mitochondrial-mediated mechanism. FASEB J. 2001;15(1):5–6.
Imbeault M, Lodge R, Ouellet M, Tremblay MJ. Efficient magnetic bead-based separation of HIV-1-infected cells using an improved reporter virus system reveals that p53 up-regulation occurs exclusively in the virus-expressing cell population. Virology. 2009;393(1):160–7.
Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem. 2003;278(28):25879–86.
Verma S, Ali A, Arora S, Banerjea AC. Inhibition of beta-TrcP-dependent ubiquitination of p53 by HIV-1 Vpu promotes p53-mediated apoptosis in human T cells. Blood. 2011;117(24):6600–7.
Yoon CH, Kim SY, Byeon SE, Jeong Y, Lee J, Kim KP, et al. p53-derived host restriction of HIV-1 replication by protein kinase R-mediated Tat phosphorylation and inactivation. J Virol. 2015;89(8):4262–80.
Fernandez Larrosa PN, Croci DO, Riva DA, Bibini M, Luzzi R, Saracco M, et al. Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway. Retrovirology. 2008;5:19.
Khan SZ, Hand N, Zeichner SL. Apoptosis-induced activation of HIV-1 in latently infected cell lines. Retrovirology. 2015;12:42.
Kim KC, Kim HG, Roh TY, Park J, Jung KM, Lee JS, et al. The effect of CD4 receptor downregulation and its downstream signaling molecules on HIV-1 latency. Biochem Biophys Res Commun. 2011;404(2):646–51.
Pan X, Zhang X, Sun H, Zhang J, Yan M, Zhang H. Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells. PLoS One. 2013;8(2):e56679.
Qi Z, Li Y, Hu J, Guo H, Zhao X, Wang G, et al. The DG75 B-cell lymphoma line exhibits biclonal immunoglobulin gene rearrangement. Biomed Rep. 2013;1(1):111–4.
Taura M, Fukuda R, Suico MA, Eguma A, Koga T, Shuto T, et al. TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. Cancer Sci. 2010;101(7):1610–7.
Yoon CH, Lee ES, Lim DS, Bae YS. PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53. Proc Natl Acad Sci U S A. 2009;106(19):7852–7.
Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, Feola D, et al. 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res. 2012;31:60.
Lee ES, Yoon CH, Kim YS, Bae YS. The double-strand RNA-dependent protein kinase PKR plays a significant role in a sustained ER stress-induced apoptosis. FEBS Lett. 2007;581(22):4325–32.
Kim HY, Choi BS, Kim SS, Roh TY, Park J, Yoon CH. NUCKS1, a novel Tat coactivator, plays a crucial role in HIV-1 replication by increasing Tat-mediated viral transcription on the HIV-1 LTR promoter. Retrovirology. 2014;11:67.
Imbeault M, Ouellet M, Tremblay MJ. Microarray study reveals that HIV-1 induces rapid type-I interferon-dependent p53 mRNA up-regulation in human primary CD4+ T cells. Retrovirology. 2009;6:5.
Freebern WJ, Smith JL, Chaudhry SS, Haggerty CM, Gardner K. Novel cell-specific and dominant negative anti-apoptotic roles of p73 in transformed leukemia cells. J Biol Chem. 2003;278(4):2249–55.
Karpinich NO, Tafani M, Schneider T, Russo MA, Farber JL. The course of etoposide-induced apoptosis in Jurkat cells lacking p53 and Bax. J Cell Physiol. 2006;208(1):55–63.
Aresvik DM, Pettersen RD, Abrahamsen TG, Wright MS. 5-fluorouracil-induced death of Jurkat T-cells--a role for caspases and MCL-1. Anticancer Res. 2010;30(10):3879–87.
Ahmadianpour MR, Abdolmaleki P, Mowla SJ, Hosseinkhani S. Gamma radiation alters cell cycle and induces apoptosis in p53 mutant E6.1 Jurkat cells. Appl Radiat Isot. 2013;71(1):29–33.
Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505(7484):509–14.
Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature. 2013;498(7454):376–9.
Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature. 2005;434(7037):1148–52.
Fevrier M, Dorgham K, Rebollo A. CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. Viruses. 2011;3(5):586–612.
Varbanov M, Espert L, Biard-Piechaczyk M. Mechanisms of CD4 T-cell depletion triggered by HIV-1 viral proteins. AIDS Rev. 2006;8(4):221–36.
Swift LH, Golsteyn RM. Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells. Int J Mol Sci. 2014;15(3):3403–31.
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253–65.
Hermankova M, Siliciano JD, Zhou Y, Monie D, Chadwick K, Margolick JB, et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol. 2003;77(13):7383–92.
We are grateful to the AIDS Research and Reference Reagent Program (ARRRP, NIH, USA) for providing cell lines (A3.01, ACH2, Jurkat and J1.1 cells).
This work was supported by intramural grants from the Korea National Institute of Health (Grant Number: 2013-N51002-00 and 2016-NG51002-00).
Availability of data and material
The datasets supporting the conclusions of this article are included within the article.
C-HY conceived the project and designed experiments. YS mainly conducted the experiments. C-HY, YS, HL, B-SC, K-CK, CK, Y-SB participated in the experimental design and the drafting of the manuscript. All authors read and approved the final manuscript.
The authors have declared that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
About this article
Cite this article
Shin, Y., Lim, H., Choi, B. et al. Highly activated p53 contributes to selectively increased apoptosis of latently HIV-1 infected cells upon treatment of anticancer drugs. Virol J 13, 141 (2016). https://doi.org/10.1186/s12985-016-0595-2
- Latently HIV-1 infected cells
- Tumor suppressor p53
- Anticancer drugs